Dieter Ayers Selected Research

Multiple Myeloma

11/2023	An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma.
10/2022	Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma.
1/2022	Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma.
10/2021	Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dieter Ayers Research Topics

Disease

5	Septic Shock (Toxic Shock Syndrome) 01/2017 - 02/2008
4	Multiple Myeloma 11/2023 - 10/2021
3	Neoplasms (Cancer) 01/2022 - 01/2019
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 11/2021 - 01/2021
3	Ischemia 01/2017 - 09/2011
1	Squamous Cell Carcinoma of Head and Neck 01/2022
1	Fabry Disease (Fabry's Disease) 04/2021
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2019
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2019
1	Acquired Immunodeficiency Syndrome (AIDS) 10/2017
1	Type 2 Diabetes Mellitus (MODY) 01/2017
1	Chagas Disease (American Trypanosomiasis) 12/2016
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 08/2013
1	Hypothyroidism 08/2013
1	Necrosis 06/2013
1	Myocardial Ischemia (Ischemic Heart Diseases) 09/2011
1	Acidosis 06/2011
1	Anemia 06/2011
1	Acute Kidney Injury (Acute Renal Failure) 01/2010
1	Renal Insufficiency (Renal Failure) 01/2010

Drug/Important Bio-Agent (IBA)

5	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2017 - 02/2008
5	Vasopressins (Vasopressin)IBA 01/2017 - 02/2008
4	idecabtagene vicleucelIBA 11/2023 - 10/2021
3	Chimeric Antigen ReceptorsIBA 10/2022 - 01/2019
3	cemiplimabIBA 11/2021 - 01/2021
2	belantamab mafodotinIBA 11/2023 - 10/2021
2	NivolumabIBA 01/2020 - 01/2019
2	TroponinIBA 06/2013 - 09/2011
1	pembrolizumabIBA 11/2021
1	Proteasome InhibitorsIBA 10/2021
1	agalsidase beta FDA Link 04/2021
1	amrubicinIBA 01/2019
1	tisagenlecleucelIBA 01/2019
1	IpilimumabIBA 01/2019
1	Topotecan (Hycamtin)FDA LinkGeneric 01/2019
1	Liraglutide FDA Link 01/2017
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2017
1	benzonidazole (benznidazole)IBA 12/2016
1	A 7 (A-7)IBA 08/2013
1	Glucagon (Glukagon)FDA Link 08/2013
1	Hemoglobins (Hemoglobin)IBA 08/2013
1	Troponin IIBA 06/2013
1	Biomarkers (Surrogate Marker)IBA 06/2013
1	MineralsIBA 06/2011
1	CatecholaminesIBA 02/2008

Therapy/Procedure

5	Therapeutics 10/2022 - 10/2017
1	Drug Therapy (Chemotherapy) 01/2019
1	Renal Replacement Therapy (Therapies, Renal Replacement) 01/2010